FDA Approves Onswik (insulin efsitora alfa-gobe) Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
RegulatoryapprovedOnswikPositive
AI Analysis
Summary
Eli Lilly announced FDA approval of Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with Type 2 Diabetes. This marks a significant regulatory milestone for the company's diabetes portfolio.
Outcome Details
FDA approval of Onswik (insulin efsitora alfa-gobe) for once-weekly basal insulin in adults with Type 2 Diabetes
Importance:8/10
Sentiment:
0.90
FDA approvalInsulin therapyType 2 DiabetesOnce-weekly dosing
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 24, 2026 8:09 PM